强化他汀治疗后冠状动脉内成像、胆固醇流出能力与外周血单核细胞转录组:YELLOW II研究
前瞻性研究纳入85例稳定型冠心病患者,经皮冠状动脉介入治疗罪犯病变后对非罪犯阻塞病变行OCT成像,并给予瑞舒伐他汀40 mg/日8至12周。复查显示最小纤维帽厚度增加(100.9±41.7 μm增至108.6±39.6 μm),胆固醇流出能力升高(0.81±0.14增至0.84±0.14,p=0.003),薄纤维帽粥样硬化斑块患病率从20.0%降至7.1%(p=0.003)。纤维帽厚度变化独立关联胆固醇流出能力增加(β=0.30,p=0.01)。
要点
- 强化瑞舒伐他汀治疗8至12周后,OCT最小纤维帽厚度由100.9±41.7 μm增至108.6±39.6 μm。
- 胆固醇流出能力由0.81±0.14升至0.84±0.14(p=0.003),薄纤维帽粥样硬化斑块患病率由20.0%降至7.1%(p=0.003)。
- 纤维帽厚度变化独立关联胆固醇流出能力增加(β=0.30,p=0.01)。
核心结论
- 纤维帽增厚与胆固醇流出能力改善独立相关,可能促成提示斑块稳定的形态学变化。
- 外周血单核细胞转录组的显著改变可能有助于判定他汀对斑块稳定的有益效应。
研究设计与样本
- 前瞻性研究,纳入85例稳定型冠心病患者,对罪犯病变行经皮冠状动脉介入治疗后,对非罪犯阻塞病变行包括OCT的冠状动脉内多模态成像。
- 所有受试者接受瑞舒伐他汀40 mg每日一次,持续8至12周,复查非罪犯病变影像并实施介入,两次均采血评估胆固醇流出能力与外周血单核细胞转录组谱。
主要发现
- 基线OCT最小纤维帽厚度为100.9±41.7 μm,随访增至108.6±39.6 μm。
- 基线胆固醇流出能力为0.81±0.14,随访增至0.84±0.14(p=0.003)。
- 薄纤维帽粥样硬化斑块患病率从20.0%降至7.1%(p=0.003)。
- 多变量分析显示纤维帽厚度变化与胆固醇流出能力增加独立相关(β=0.30,p=0.01)。
- 外周血单核细胞微阵列分析检出随访较基线差异表达的117个基因,包括胆固醇合成(SQLE)、脂肪酸不饱和度调节(FADS1)、细胞胆固醇摄取(LDLR)、流出(ABCA1和ABCG1)及炎症(DHCR24)相关基因;加权共表达网络分析显示与纤维帽厚度和胆固醇流出能力有利变化相关的独特基因簇。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite extensive evidence demonstrating the beneficial effects of statins on clinical outcomes, the mechanisms underlying these effects remain elusive. OBJECTIVES: This study assessed changes in plaque morphology using intravascular imaging, with a comprehensive evaluation of cholesterol efflux capacity (CEC) and peripheral blood mononuclear cell (PBMC) transcriptomics in patients receiving high-dose statin therapy. METHODS: In a prospective study, 85 patients with stable coronary artery disease underwent percutaneous coronary intervention for a culprit lesion, followed by intracoronary multimodality imaging, including optical coherence tomography (OCT) of an obstructive nonculprit lesion. All subjects received 40 mg of rosuvastatin daily for 8 to 12 weeks, when the nonculprit lesion was reimaged and intervention performed. Blood samples were drawn at both times to assess CEC and transcriptomic profile in PBMC. RESULTS: Baseline OCT minimal fibrous cap thickness (FCT) was 100.9 ± 41.7 μm, which increased to 108.6 ± 39.6 μm at follow-up, and baseline CEC was 0.81 ± 0.14, which increased at follow-up to 0.84 ± 0.14 (p = 0.003). Thin-cap fibroatheroma prevalence decreased from 20.0% to 7.1% (p = 0.003). Changes in FCT were independently associated with CEC increase by multivariate analysis (β: 0.30; p = 0.01). PBMC microarray analysis detected 117 genes that were differentially expressed at follow-up compared to baseline, including genes playing key roles in cholesterol synthesis (SQLE), regulation of fatty acids unsaturation (FADS1), cellular cholesterol uptake (LDLR), efflux (ABCA1 and ABCG1), and inflammation (DHCR24). Weighted coexpression network analysis revealed unique clusters of genes associated with favorable FCT and CEC changes. CONCLUSIONS: The study demonstrated an independent association between fibrous cap thickening and improved CEC that may contribute to morphological changes suggesting plaque stabilization among patients taking intensive statin therapy. Furthermore, the significant perturbations in PBMC transcriptome may help determine the beneficial effects of statin on plaque stabilization. (Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering [YELLOW II]; NCT01837823).
引用
- Kini AS, Vengrenyuk Y, Shameer K, et al. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment: The YELLOW II Study. J Am Coll Cardiol. 2016. PMID: 27989886. doi:10.1016/j.jacc.2016.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。